Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujata Patil

Showing results (181-190 of 230) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Cancer|July 21, 2021
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinomaAndrew W Silagy, Ritesh R Kotecha, Stanley Weng, et al.
NPJ Breast Cancer|March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumabEmanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
JCO Precision Oncology|December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast CancerKomal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
The Oncologist|February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center ExperienceJasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
JAMA Network Open|January 6, 2026
Racial and Ethnic Disparities in Persistent Chemotherapy-Induced Alopecia Among Women With Breast CancerDanbee Kang, Lukas Kraehenbuehl, Haseen Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell TumorsDarren R Feldman, James Hu, Tanya B Dorff, et al.
Contemporary Clinical Trials|May 23, 2021
The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivorsTalya Salz, Jamie S Ostroff, Chandylen L Nightingale, et al.
The Oncologist|February 15, 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell TumorsSamuel A Funt, Deaglan J McHugh, Stephanie Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerChau Dang, Neil Iyengar, Farrah Datko, et al.
Pageof 23

Showing results (181-190 of 230) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Cancer|July 21, 2021
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinomaAndrew W Silagy, Ritesh R Kotecha, Stanley Weng, et al.
NPJ Breast Cancer|March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumabEmanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
JCO Precision Oncology|December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast CancerKomal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
The Oncologist|February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center ExperienceJasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
JAMA Network Open|January 6, 2026
Racial and Ethnic Disparities in Persistent Chemotherapy-Induced Alopecia Among Women With Breast CancerDanbee Kang, Lukas Kraehenbuehl, Haseen Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell TumorsDarren R Feldman, James Hu, Tanya B Dorff, et al.
Contemporary Clinical Trials|May 23, 2021
The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivorsTalya Salz, Jamie S Ostroff, Chandylen L Nightingale, et al.
The Oncologist|February 15, 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell TumorsSamuel A Funt, Deaglan J McHugh, Stephanie Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerChau Dang, Neil Iyengar, Farrah Datko, et al.
Pageof 23